Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philadelphia chromosome positive acute lymphoblastic leukaemia

- PMLiVE

Amgen sets premium price for Blincyto

Leukaemia drug becomes one of the most expensive pharma products on the market

- PMLiVE

NICE backs GSK drug for leukaemia

Arzerra on course for NHS use in blood cancer

- PMLiVE

Janssen’s blood cancer drug Imbruvica approved in Europe

European commission licenses the first-in-class drug for two rare diseases

- PMLiVE

EMA safety panel rules no change needed for Ariad’s Iclusig

Positive news comes after blood clot concerns

- PMLiVE

Servier signs cancer collaboration with Cellectis

Will target leukaemia and five solid tumours

- PMLiVE

FDA clears J&J’s Imbruvica for leukaemia

Adds to cancer drug's lymphoma indication

- PMLiVE

Ariad’s cancer drug to remain on EU market

But EMA restricts use of Iclusig due to blood clot risk

- PMLiVE

EMA to review safety of Ariad’s Iclusig

Product information will be updated to warn of blood clot risk

- PMLiVE

Ariad cuts 160 jobs in US after Iclusig suspension

Feels effect of FDA decision to suspend cancer drug on safety concerns

- PMLiVE

FDA suspends sale of Ariad’s cancer drug

Iclusig linked to increased risk of blood clots

- PMLiVE

Janssen submits blood cancer drug in EU

Seeks EMA approval for ibrutinib

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links